Shubham Pant, MD: The first thing people say when people hear “tumor” is, “Oh my God, I’m going to die, this is a tumor.” But tell me, as a doctor who treats neuroendocrine tumors, there can be ...

Shubham Pant, MD: So, Larry, when you first met Dr. Morse, what kind of questions did you have for him? You had done all your research before or did you do it after? Larry Pleasant: No, I hadn’t. I ...

Carcinoid syndrome is a rare condition that occurs in patients with gastrointestinal tumors. These patients secrete an excessive amount of serotonin, which can lead to symptoms like frequent diarrhea, ...

As Crinetics prepares to make a tilt for FDA approval in a rare growth disorder later this year, a topline readout from a phase 2 study suggests the same drug also has the potential to treat symptoms ...

Very little is known about the causes of gastrointestinal carcinoid tumors. As with other cancers, scientists have recognized some changes in the DNA of carcinoid tumor cells that are probably ...

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s AMYT lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most common ...

The digestive system processes food for energy and rids the body of solid waste. After food is chewed and swallowed, it enters the esophagus, a tube-shaped organ that carries food to the stomach ...

Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does ...